Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 30, 2021 10:46am
126 Views
Post# 33100881

RE:RE:remember this?

RE:RE:remember this?TH is executing well on medical research in cancer and NASH, and Marsolais and his team deserve a ton of credit for that, but the issue is they are not getting much credit for that from the market because they have not been able to get investors interested in their progress. A slick video distributed in a way that investors might see it certainly would help. Can't see how it would hurt. Whatever TH has done regarding marketing their impressive progress to investors has clearly not worked very well, so TH should be open to new ideas.

qwerty22 wrote:

They are executing on a medical research business and you're complaining about videos.

 

scarlet1967 wrote:

 

"3D animations are great support to explain the mechanism of action of a molecule. With the help of Amerra, we were able to convey how our promising peptide-drug conjugate technology works inside the body. Amerra  produced such an amazing result at a cost a small biotech like us can afford. We're very much looking forward to working with them on our next animated video."
- Nichol Pelchat, Associate Director, New Product Planning

https://youtu.be/6iu07e1_us8

Yet they are quite generous with their compensations which was announced on a Friday afternoon thus less attention. So whose interest has been prioritized using the funds for a cash strapped company? the employees with fat bonuses or decent marketing to support the valuation of the company subsequently a decent ROI for their loyal long-term shareholders?




<< Previous
Bullboard Posts
Next >>